AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00384748 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-home messaging device.
Description: The purpose of this aspect of the intervention is to screen for unforeseen problems and to reinforce adherence to the recommended treatment. It will be used to interface with patients daily, but briefly. The in-home messaging device, which resembles a caller ID box is attached to the home telephone line and electrical outlet. Installation of the equipment involves connecting it to the phone line and plugging it into an electrical outlet. The teletherapist receives the clinical data from the in-home messaging device via the internet on a daily basis. It is used to screen for depression, lower extremity strength, self-care tasks and mobility, falls and exercise adherence.
Study NCT00384748 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Routine VA care.
Study NCT02787421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breathe-Rite Nasal Dilator Strip
Description: During the pre-operative clinic visit, participants will be given a Breathe-Rite Nasal Dilator Strip
Study NCT02702388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib capsule.
Study NCT02702388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib matching placebo
Description: Lenvatinib matching placebo capsule.
Study NCT04830111 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: heart rate variability biofeedback Application (Eureka iDestressor)
Description: heart rate variability biofeedback protocol duration time is 10 min twice/day for 5days
Study NCT04092959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chinese square dancing group
Description: Chinese square dances have been selected from 24 sets of square dances jointly launched in 2015 and 2017. According to the age and physical health status of the subjects, six dance pieces of are selected as the repertoires of the intervention in this study. Subjects in this group perform exercise consisting of Chinese square dances for 30-60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months. Each training includes 5 min warm-up and 5 min cool-down , and the exercise should start after meals for 1 hour. Make the subjects step for 30 s to 1 min between each track to adjust the heart rate. Heart rate is monitored by sports bracelet. Subjects using β-blockers will not use heart rate to monitor exercise intensity, but RPE scores. And RPE( Borg scale) scores are ranged from 11-13.
Study NCT04092959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group
Description: Walking group , Chinese square dancing group and control group are given the same health education brochures or health education lectures once a month . Specific contents of the brochure or lecture include : type 2 diabetes , hypertension related medical knowledge and the significance of intervention treatment ; prevention of type 2 diabetes , hypertension nutrition and exercise recommendations ; basic knowledge of scientific exercise and its matters needing attention .
Study NCT03862105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Health app tool - Twistle
Description: The investigators propose to use radical cystectomy as a model to examine the utilization of an electronic, internet-based mobile health intervention that can prospectively collect Patient Reported Outcome data while providing timely feedback to patients and clinicians. This mobile health intervention will utilize a well-established platform (Twistle) that can be accessed through multiple technologies, including laptops, smartphones, and other computer-based systems.
Study NCT02025985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Route of administration and dosage form: Oral tablet; Doses: 35 mg/m\^2 BIW, 35 mg/m\^2 QW, 50 mg/m\^2 BIW, 50 mg/m\^2 QW, 60 mg/m\^2 BIW, 60 mg/m\^2 QW.~Treatment cycles were 4 weeks each i.e., 28 day cycles.
Study NCT04679311 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High ACE Activity Fresh Frozen Plasma
Description: Subjects will be treated with fresh frozen plasma that has been preselected for ACE activity content of ≥ 50 U/L
Study NCT04679311 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Subjects will be treated with normal saline 500 cc
Study NCT04046770 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug administration and Flushing procedure using Double-Chamber Syringe
Description: The new device will allow the professional to conduct all the procedure (assure the patency/enables the pre-flushing), drugs administration and flushing, using only one device.
Study NCT04046770 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug administration and Flushing procedure using Classic Syringe
Description: To fully complete the intravenous drug administration with rigor, nurses should flush the catheter pre, post and inbetween drug administration. This implies the use of two or three syringes.
Study NCT03369652 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication review
Description: Conducted by the pharmacist and discussed with hospital physician
Study NCT04072198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg every 2 weeks for 8 cycles followed by maintenance
Study NCT04072198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg every 2 weeks for 8 cycles followed by maintenance
Study NCT04377230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biliopancreatic limb length of 60cm.
Description: Roux-en- Y gastric bypass will be performed with a biliopancreatic limb length of 60cm.
Study NCT04377230 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: biliopancreatic limb length of 100cm.
Description: Roux-en- Y gastric bypass will be performed with a biliopancreatic limb length of 100cm.
Study NCT03329898 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dried biological amnion graft
Description: dried biological amnion graft. The amnion grafts were spread on the balloon end of disposable balloon uterine stent .
Study NCT03329898 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: disposable balloon uterine stent
Description: the disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus.
Study NCT03329898 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: disposable balloon uterine stent
Description: the disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus.
Study NCT03329898 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: estradiol valerate tablets
Description: oral estradiol valerate tablets, which can promote endometrial growth after operation.
Study NCT03329898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol valerate tablets
Description: oral estradiol valerate tablets, which can promote endometrial growth after operation.
Study NCT03329898 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: dydrogesterone Tablets
Description: oral dydrogesterone Tablets
Study NCT03329898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dydrogesterone Tablets
Description: oral dydrogesterone Tablets
Study NCT01762150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 400mg BID by oral until progressed;
Study NCT01762150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine: 1000mg/m2, administered by intravenous drip for 30\~60min on Day 1 and 8,for 4 cycles;
Study NCT01762150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin: 25mg/m2, administered by intravenous drip on Day 1-3, with appropriate liquid hydration,for 4 cycles.
Study NCT02579564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT02579564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Study NCT02579564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Study NCT02579564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Study NCT02579564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT02579564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study NCT02579564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Study NCT02579564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Study NCT02579564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oncorine
Study NCT02579564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Study NCT02579564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT04072198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 165 mg/m2 every 2 weeks for 8 cycles
Study NCT02579564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Study NCT01665950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: The study uses the Sequential Parallel Comparison design (SPCD), with two 4-week phases: n=30 subjects are randomized 1:1 to simvastatin versus placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 for a further 4 weeks. The SPCD will allow us to pool data from both phases to estimate the simvastatin treatment effect. Subjects who respond in phase 1, and all subjects who receive simvastatin in phase 1, continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed. Dosage for simvastatin or matched placebo 20mg daily for 8 weeks.
Study NCT01665950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects (n=15) are randomized to placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 to statin vs placebo for a further 4 weeks. Subjects who respond in phase 1 continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed. Dosage for simvastatin or matched placebo 20mg daily for 8 weeks.
Study NCT01665950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects (n=15) are randomized to placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 to statin vs placebo for a further 4 weeks. Subjects who respond in phase 1 continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed. Dosage for simvastatin or matched placebo 20mg daily for 8 weeks.
Study NCT04536012 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamification and Social Incentives
Description: Participants in the intervention arm will receive gamification and social incentives as part of the intervention. See arm descriptions for more detail.
Study NCT01971775 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonically activated Shears
Description: Dissection and lymphovascular sealing with Ultrasonically Activated Shears
Study NCT01971775 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Monopolar Electrocautery
Description: Dissection and lymphovascular sealing with Conventional Monopolar Electrocautery
Study NCT01356303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin, docetaxel
Description: All patients met the eligibility criteria will undergo treatment with chemotherapy.~Each cycle of chemotherapy administration will be started with docetaxel at dose of 75 mg/m2 in 250 ml of Dextrose 5% in Water or Normal Saline administered as a 1-hour intravenous infusion followed by cisplatin at dose of 75 mg/m2 administered as a 2-hour intravenous infusion every 3 weeks per cycle for totally 4-6 cycles.
Study NCT03841058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abaloparatide
Description: 80 mcg delivered SC by a pen
Study NCT02088151 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selective retinal pigment epithelium laser therapy using the R:GEN Laser System
Description: Patients receive selective retinal pigment epithelium laser treatment using the R:GEN Laser System by Lutronic Corporation, Korea.
Study NCT00676182 — intervention group
Intervention type: OTHER
Intervention: Telerehabilitation
Description: Rehabilitation via computer assisted internet capabilities
Study NCT04069325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simiaowan
Description: pills, 6g twice daily (BID), oral, 12 weeks
Study NCT04069325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: pills, 6g twice daily (BID), oral, 12 weeks
Study NCT04069325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: febuxostat
Description: tablets, 40 mg once daily (QD), oral, 12 weeks
Study NCT04069325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: febuxostat
Description: tablets, 40 mg once daily (QD), oral, 12 weeks
Study NCT03372330 — intervention group
Intervention type: DRUG
Intervention: Standard care for sepsis and PAD
Description: The standard medications care for the patient with PAD included antiplatelet agents.
Study NCT03372330 — intervention group
Intervention type: DRUG
Intervention: Standard care for sepsis
Description: The standard care for the patient with sepsis.
Study NCT04358172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 'Oral and Denture Guide' mobile application
Description: 'Oral and Denture Guide' mobile application provides evidence-based information about cleaning aids and material for dentures, denture care and oral hygiene instructions.
Study NCT01631890 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound assisted endoscopic glue injection
Description: N Butyl cyanoacrylate will be used for achieving initial hemostasis during active gastric variceal bleed and during follow up gastric variceal obturation. Endoscopic injection will be performed intravariceally using a therapeutic endoscope and a steel hubbed catheter, with N-butyl-2-cyanoacrylate. The cyanoacrylate will be injected without dilution with lipiodol. The tip of the endoscope will be coated with lipiodol to prevent sticking of glue to the endoscope. The injection catheter is primed with saline solution followed by injection of glue in 1ml aliquot to fill the dead space followed by injection of sterile water to flush the glue into the varix. The needle is withdrawn immediately after the glue injection to prevent tissue adherence.
Study NCT01631890 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Endotherapy
Description: Patients will be stabilized by giving i/v fluids, blood and blood products. Injection terlipressin will be given to all patients in a bolus dose of 2mg within 30 minutes of admission to the hospital. This would be followed by 1mg i/v 6hrly and will be continued for 5 days. If terlipressin cannot given then inj.somatostatin 500mcg IV bolus followed by 250mcg/hr continuous infusion for 5days.
Study NCT03093116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral repotrectinib (TPX-0005)
Description: Oral repotrectinib (TPX-0005) capsules.
Study NCT03323619 — intervention group
Intervention type: PROCEDURE
Intervention: anesthesia type
Description: No intervention. General anesthesia or local anesthesia with sedation are decided by the physicien according to his usual practice
Study NCT04072198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2 every 2 weeks for 8 cycles
Study NCT04072198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200 mg/m2 every 2 weeks for 8 cycles
Study NCT04072198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoruracil
Description: 3200mg/m2 every 2 weeks for 8 cycles
Study NCT00585208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramelteon
Description: Ramelteon 8mg daily
Study NCT00585208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo for ramelteon 8mg daily
Study NCT01623622 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once or more / week
Study NCT01950988 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Manual toothbrush reference
Study NCT01950988 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Measure of the dental plaque
Study NCT03841058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abaloparatide
Description: 80 mcg delivered SC by a pen
Study NCT03841058 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A pen to deliver a SC dose of placebo
Study NCT01637454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Noradrenaline
Description: Patients in group B received a continuous infusion of noradrenaline at an initial dose of 0.5 mg/hour, designed to achieve an increase in mean arterial pressure (MAP) of at least 10mmHg or an increase in 4-h urine output to more than 200 mL. When one of these goals was not achieved, the noradrenaline dose increased every 4 hour in steps of 0.5 mg/hour, up to the maximum dose of 3 mg/hour
Study NCT03764449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Balovaptan
Description: In Period 1, balovaptan was administered as a single oral dose.~In Period 2, balovaptan was administered as an oral dose once daily on Day 1 to Day 14.
Study NCT01950988 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Manual toothbrush Broscyl®
Study NCT00712595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Oral administration of Mifepristone 10 mg daily for three months
Study NCT00712595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Oral administration of Mifepristone 5 mg, daily for three months
Study NCT01637454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: Patients in group A received terlipressin as an intravenous bolus of 0.5 mg every 6 h. If a significant reduction in serum creatinine level (≥1 mg/dL) was not observed during 3-day period, the dose of terlipressin was increased in a stepwise fashion every 3 days to a maximum of 2 mg every 6 hour
Study NCT04439214 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT04164108 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intermittent Enteral Nutrition Protocol
Description: Patients will receive total recommended nutrition divided into four equal meals, delivered at a rate of 400 cc/hr at 8:00, 12:00, 16:00, 20:00. Titration schedule will include administering 50% of volume for first two feeds, then 75%, and then 100%.
Study NCT01356043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-amlodipine 5mg,Telmisartan 80mg
Description: S-amlodipine 5mg and Telmisartan 80mg, Oral, Once a day, for 9 days + Wash out (19 days)
Study NCT01356043 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-amlodipine 5mg
Description: S-amlodipine 5mg, Oral, Once a day, for 9 days + Wash out(19 days)
Study NCT03862131 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MyoStrain®
Description: MyoStrain® SENC software receives image data from MRI storage archives and performs viewing, image manipulation, communication, printing, and quantification of images.
Study NCT03862131 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyoStrain®
Description: MyoStrain® SENC software receives image data from MRI storage archives and performs viewing, image manipulation, communication, printing, and quantification of images.
Study NCT00776295 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combined adenovirus vectored p53 tranfected dedritic cell vaccine and ex vivo expanded T-lymphocytes
Description: Autologous Dendritic Cells Derived from Peripheral Blood Mononuclear Cells, Cultured with Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin 4, Transfected with Adenovirus Vector (Ad5CMV-p53, Introgen Therapeutics) Expressing Wildtype p53 Gene; Combined with Autologous Expanded T Lymphocytes (CD3+, CD4+, and CD8+), Cultured with OKT3 (Orthoclone) and Anti-CD28 (Repligen) Coated Magnetic Beads
Study NCT02589990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength training
Description: see arm description
Study NCT00060203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brostallicin
Description: Patients receive brostallicin IV over 10-30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of brostallicin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity.
Study NCT00860197 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fully torrefied coffee
Description: Fully torrefied coffee
Study NCT00860197 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Partially torrefied coffee
Description: Partially torrefied coffee
Study NCT00557011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRP104
Description: 30 mg, 50 mg or 70 mg capsules taken orally once daily in the morning
Study NCT00557011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adderall XR
Description: 10 mg capsules taken once daily in the morning at dosages of either 1x10mg, 2x10mg or 3x10mg